{
    "clinical_study": {
        "@rank": "141211", 
        "arm_group": {
            "arm_group_label": "LiRIS\u00ae  400 mg", 
            "arm_group_type": "Experimental", 
            "description": "LiRIS\u00ae 400 mg (Lidocaine Releasing Intravesical System 400 mg); a drug-device combination product, placed in the urinary bladder, and releases lidocaine into the bladder over a 14 day period."
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate if LiRIS 400 mg is safe and tolerable when\n      administered to women with  Interstitial Cystitis with Hunner's lesions, and  to evaluate\n      any change in the bladder or in IC symptoms, following LiRIS administration."
        }, 
        "brief_title": "A Safety, Tolerability and Preliminary Efficacy Study of LiRIS\u00ae 400 mg in Women With Interstitial Cystitis (IC)and Hunner's Lesions", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Interstitial Cystitis", 
        "condition_browse": {
            "mesh_term": [
                "Cystitis", 
                "Cystitis, Interstitial"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women age 18 and older\n\n          -  Interstitial Cystitis with history of Hunner's lesions in the bladder\n\n          -  Moderate to severe bladder discomfort\n\n          -  Confirmation of Hunner's lesions in Bladder\n\n          -  Able to report symptom (pain and voiding frequency) in a diary throughout the study\n\n        Exclusion Criteria:\n\n          -  Pregnant women\n\n          -  History or presence of bladder cancer\n\n          -  History or presence of any condition that would make it difficult to evaluate\n             bladder symptoms"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01879683", 
            "org_study_id": "TAR-100-105"
        }, 
        "intervention": {
            "arm_group_label": "LiRIS\u00ae  400 mg", 
            "description": "LiRIS\u00ae 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the  bladder for  up to  14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.", 
            "intervention_name": "LiRIS\u00ae 400 mg", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Hunner's lesion", 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Royal Oak", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48073"
                }, 
                "name": "William Beaumont Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of LiRIS\u00ae 400 mg in Women With Ulcerative Interstitial Cystitis", 
        "overall_official": {
            "affiliation": "William Beaumont Hospitals", 
            "last_name": "Kenneth Peters, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in appearance of Hunner's Lesion.", 
            "safety_issue": "No", 
            "time_frame": "Study Day 14 or 28"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01879683"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Subjects rate symptom of bladder pain for 5 days during screening, daily during treatment (study days 0 to 14), and for 3 days prior to follow up visits at  1,2, and 4 weeks after treatment.  Subjects also record each daytime and night time void for 3 days during screening, and for 3 days prior to visits on study days 7 and 14, and the follow up visits at 1,2, and 4 weeks after treatment.", 
            "measure": "Change from baseline in subject reported IC symptoms (bladder pain, urinary frequency)", 
            "safety_issue": "No", 
            "time_frame": "Screen (Day -5 to -1);  during treatment (Day 0 - 14) and on designated days during follow up period of 4 weeks after treatment."
        }, 
        "source": "TARIS Biomedical, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "TARIS Biomedical, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}